Tesamorelin / Ipamorelin
Chemical and Molecular Data for Tesamorelin
| Compound Name | Tesamorelin |
|---|---|
| Synonyms / Alt Names | TH9507; TH 9507; tesamorelina |
| CAS Number | 804475-66-9 |
| Chemical Formula | C221H366N72O67S |
| Molecular Weight | 5136 g/mol |
| IUPAC Name | (4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-2-[[(2S)-2-[[(E)-hex-3-enoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-5-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| InChIKey | QBEPNUQJQWDYKU-BMGKTWPMSA-N |
| SMILES Code | CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N |
Chemical and Molecular Data for Ipamorelin
| Compound Name | Ipamorelin |
|---|---|
| Synonyms / Alt Names | NNC-26-0161; Aib-His-D-2-Nal-D-Phe-Lys-NH2; NNC-260161 |
| CAS Number | 170851-70-4 |
| Chemical Formula | C38H49N9O5 |
| Molecular Weight | 711.9 g/mol |
| IUPAC Name | (2S)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide |
| InChIKey | NEHWBYHLYZGBNO-BVEPWEIPSA-N |
| SMILES Code | CC(C)(C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@H](CC2=CC3=CC=CC=C3C=C2)C(=O)N[C@H](CC4=CC=CC=C4)C(=O)N[C@@H](CCCCN)C(=O)N)N |
What is the Tesamorelin / Ipamorelin Blend?
The Tesamorelin / Ipamorelin Blend is an advanced, dual-action peptide formulation combining two distinct growth hormone secretagogues in a precise 8MG / 2MG ratio. Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH) modified with a trans-3-hexenoic acid group to extend its metabolic lifespan. Ipamorelin is a highly selective pentapeptide ghrelin receptor agonist belonging to the growth hormone secretagogue (GHS) class. Together, they target alternative signaling pathways in the pituitary gland to induce a powerful, synergistic release of endogenous growth hormone. Researchers study this specific combination for its potential to accelerate visceral fat lipolysis, enhance lean muscle mass retention, and optimize cellular metabolic efficiency.
For laboratory and in vitro evaluation, researchers often choose to buy the Tesamorelin / Ipamorelin Blend in high-purity lyophilized form. Reconstituted solutions can be securely prepared using specialized laboratory buffers or a compatible reconstitution solution to preserve peptide structure and prevent premature degradation during cellular validation screening.
What are the Mechanisms of Action?
The biochemical pathways and cellular targets of the Tesamorelin / Ipamorelin Blend include:
- Complementary Pituitary Pathway Activation: This formulation leverages a dual-signal mechanism. Tesamorelin binds directly to growth hormone-releasing hormone receptors (GHRHR) on pituitary somatotropes to stimulate synthesis, while Ipamorelin targets the growth hormone secretagogue receptor (GHS-R/ghrelin receptor). This simultaneous activation triggers an amplified, synergistic secretion cascade that far exceeds the performance of either peptide administered alone.
- Lipolytic and Visceral Adipose Tissue Targeting: Tesamorelin specifically stimulates peripheral lipolysis cascades. By escalating endogenous growth hormone availability, it downregulates fat storage enzymes and interacts directly with adipocyte receptors to promote the clearing of deep visceral adipose tissue (VAT).
- Highly Selective Secretagogue Expression: Unlike traditional, less refined secretagogues, Ipamorelin is exceptionally selective. It amplifies growth hormone pulse amplitudes while remaining completely inert at the receptors regulating cortisol, prolactin, or aldosterone, protecting the research environment from unwanted stress-hormone cross-reactivity.
What are the Clinical & Preclinical Trials on the Tesamorelin / Ipamorelin Blend?
When evaluating research efficacy and published experimental literature for the Tesamorelin / Ipamorelin Blend:
- Visceral Fat Reduction Dynamics: Landmark clinical evaluations focusing on the Tesamorelin component demonstrated highly significant, repeatable reductions in visceral adipose tissue and waist circumference metrics. The data confirmed substantial drops in deep trunk fat profiles alongside positive shifts in circulating insulin-like growth factor 1 (IGF-1) concentrations.
- Pulsatile Secretion Stability: Preclinical screening models examining Ipamorelin confirmed its unique ability to perfectly mimic natural, pulsatile growth hormone patterns. Rather than creating a flat baseline surge that risks pituitary receptor desensitization, it maintains healthy, default homeostatic endocrine feedback dynamics.
- Synergistic Mass Optimization: In vitro tissue profiles and animal assays combining GHRH and GHS-R agonists show that simultaneous administration significantly improves nitrogen retention and cellular protein synthesis rates, accelerating muscle cell proliferation metrics compared to isolated controls.
How does the Blend compare to other compounds?
To evaluate absolute receptor affinity, signal duration, and tissue metabolic impacts, researchers compare the Tesamorelin / Ipamorelin Blend against its individual components and alternative long-acting GHRH formulations:
| Compound | Primary Target | Structural Modifications | Biological Impact / Receptor Affinity |
|---|---|---|---|
| Tesamorelin / Ipamorelin Blend | GHRH Receptor & GHS-R (Ghrelin Receptor) simultaneously | 8MG stabilized hexenoyl-GHRH analog paired with a 2MG selective pentapeptide secretagogue | Triggers an amplified, synergistic release of growth hormone; optimized for visceral fat reduction and muscle retention without stress-hormone cross-reactivity |
| Tesamorelin (Standalone) | GHRH Receptor (Selective Agonist) | Human GHRH (1-44) sequence bound to a trans-3-hexenoic acid N-terminal anchor | Strong lipolytic action tailored specifically for visceral adipose tissue, but lacks the secondary amplification provided by ghrelin pathway activation |
| Ipamorelin (Standalone) | GHS-R (Ghrelin Receptor Agonist) | Pure synthetic pentapeptide structure omitting traditional GHRH sequence configurations | Provides highly selective, clean pulsatile growth hormone releases, but its standalone performance is capped by the availability of baseline endogenous GHRH levels |
| CJC-1295 w/DAC | GHRH Receptor (Continuous Long-Acting Agonist) | Tetra-substituted GHRH (1-29) fragment modified with a C-terminal Drug Affinity Complex (DAC) | Binds covalently to serum albumin to yield a long biological half-life (6-8 days), creating a sustained elevate baseline release rather than mimicking rapid pulsatile dynamics |
Shipping & Returns
Same-Day Dispatch
Orders before 4 PM CT Mon–Fri ship same day. Weekend and holiday orders ship the next business day.
Carriers
U.S. shipping via FedEx. FedEx 2Day $15, FedEx Priority Overnight $60. Free shipping on U.S. orders over $200. Prices exclude tax.
Returns
Returns and exchanges for damaged or defective products only. Contact us within 14 days of delivery with your order number and photos.
Full details: Shipping Policy and Refund Policy.
Disclaimer: All compounds and research materials provided by Essential Aminos are strictly for laboratory and research professional use only. They are not approved for human or animal use nor consumption by the Food and Drug Administration (FDA). These products should not be used for any form of in vivo experimentation or for any other non-laboratory purpose. Any violation or indication of human or animal use will result in immediate removal from being able to purchase products in the future. By purchasing these products, you acknowledge that they will be used exclusively within a controlled and qualified research environment.
Certificate of Analysis
Certificates of analysis are provided for laboratory research reference. Expand a batch below to view the PDF. Only the newest three COAs for this product are listed here.
Tesamorelin/Ipamorelin 8MG/2MG - Lot / Batch: BX-P-E7K4
- Mass Identification: Confirmed
- Average Purity: 99.82%
- Endotoxin Threshold Results: Pass
- Lot#: BX-P-E7K4
- Search Code: Esse2608030028
Search all COAs by batch number (includes older batches not shown above).
